One biologic comes out on top in psoriatic arthritis trial
It's the first direct comparison of adalimumab and ixekizumab for the condition
The first head-to-head trial of two biologics for psoriatic arthritis suggests that, while adalimumab and ixekizumab are both effective, ixekizumab may have the edge in patients with active skin disease.
The SPIRIT H2H clinical trial, funded by Eli Lilly and Company, which makes ixekizumab, compared 24-week results for 269 people randomised to the tumour necrosis factor (TNF) inhibitor, adalimumab, with 262 randomised to the interleukin 17A (IL-17A) antagonist, ixekizumab.
